retatrutide clinical trials phase Retatrutide: A Promising Option for Non-Diabetic Weight Loss in New Retatrutide Phase 3 Trial

Zepbound vs Semaglutide GLP-1 vs Wegovy Q&A Zepbound is an injectable, prescribed medicine that may help people with obesity or excess weight who may have weight-related medical conditions lose weight and maintain it

Some women find their levothyroxine needs shift not just from weight loss but from changing estrogen levels simultaneously

For Saxenda, treatment should be discontinued if less than 5% weight loss is achieved after 12 weeks at the 3 mg daily dose

$106 billion is spent annually on reduced productivity

If you're already several weeks or months into GLP-1 therapy, it's not too late

Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes management but may be prescribed off-label for weight management at a clinician's discretion